Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-07-02

Clinical Trial Update: Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating interleukin-2 in relapsed or refractory acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Interleukin-2 (interleukin-2)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Leukemia | Phase 2 | Status: COMPLETED